Frontiers in Medical Science Research, 2024, 6(6); doi: 10.25236/FMSR.2024.060602.
Qi Tang, Yao Shen
Key Laboratory of Laboratory Medicine, Ministry of Education, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, China
Carnosine is a dipeptide, which plays a variety of biological activities in different tissues, given its easy brain barrier permeability, and minimal side effects, indicating potential in glioma therapy. In this paper, the effects of carnosine on the proliferation and glycolysis of U87 and U251 cells were discussed. U87 and U251 cells were treated with 50 mmol/L carnosine for 72 h under normoxia (21% O2) and hypoxia (1% O2), cell viability, clonogenicity, and proliferation were assessed via MTT, clonogenic, and Edu assays. Glucose, lactate, ATP, G6P kits were used to detect changes in glucose, lactate, ATP and G6P content. Western Blotting assessed AMPK, p-AMPK, GLUT1, and PFK1 protein expressions. Intracellular glycolytic intermediates were analyzed via 13C-labeled metabolic flux analysis. Carnosine can inhibit the glycolytic metabolism of glioma U87 and U251 cells, thereby inhibiting the proliferation of tumor, and its mechanism may be related to the reduction of the expression of glycolysis-related enzymes GLUT1 and PFK1, and the expression of p-AMPK.
Carnosine; Glioma cells; Glycolysis; Metabolic flux analysis
Qi Tang, Yao Shen. Carnosine as a Glycolysis Modulator: Implications for Glioma Cell Growth Inhibition. Frontiers in Medical Science Research (2024), Vol. 6, Issue 6: 8-16. https://doi.org/10.25236/FMSR.2024.060602.
[1] Ostrom QT, Gittleman H, Truitt G, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015 [J]. Neuro Oncol. 2018; 20(suppl4): iv1-iv86.
[2] Wen PY, Weller M, Lee EQ, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions [J]. Neuro Oncol. 2020;22(8):1073-1113.
[3] Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet? [J]. Neuro Oncol. 2013;15(1):4-27.
[4] Gariballa SE, Sinclair AJ. Carnosine: physiological properties and therapeutic potential[J]. Age Ageing. 2000;29(3):207-210.
[5] Holliday R, McFarland GA. Inhibition of the growth of transformed and neoplastic cells by the dipeptide carnosine[J]. Br J Cancer. 1996;73(8):966-971.
[6] Schön M, Mousa A, Berk M, et al. The Potential of Carnosine in Brain-Related Disorders: A Comprehensive Review of Current Evidence[J]. Nutrients. 2019;11(6):1196.
[7] Cheng JY, Yang JB, Liu Y, et al. Profiling and targeting of cellular mitochondrial bioenergetics: inhibition of human gastric cancer cell growth by carnosine[J]. Acta Pharmacol Sin. 2019;40(7):938-948.
[8] Hwang B, Shin SS, Song JH, et al .Carnosine exerts antitumor activity against bladder cancers in vitro and in vivo via suppression of angiogenesis[J]. J Nutr Biochem. 2019;74: 108230.
[9] Hsieh SL, Li JH, Dong CD,et al. Carnosine suppresses human colorectal cancer cell proliferation by inducing necroptosis and autophagy and reducing angiogenesis[J]. Oncol Lett. 2022; 23(2):44.
[10] Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation [J]. Annu Rev Cell Dev Biol. 2011; 27: 441-464.
[11] Vander Heiden MG, Locasale JW, Swanson KD, et al. Evidence for an alternative glycolytic pathway in rapidly proliferating cells[J]. Science. 2010;329(5998):1492-1499.
[12] Hamanaka RB, Chandel NS. Targeting glucose metabolism for cancer therapy[J]. J Exp Med. 2012; 209(2):211-215.
[13] Renner C, Asperger A, Seyffarth A, et al. Carnosine inhibits ATP production in cells from malignant glioma [J]. Neurol Res. 2010;32(1):101-105.
[14] Kitamura K, Hatano E, Higashi T, et al. Proliferative activity in hepatocellular carcinoma is closely correlated with glucose metabolism but not angiogenesis[J]. J Hepatol. 2011;55: 846–857.
[15] Chen B, Tang H, Liu X, et al. miR-22 as a prognostic factor targets glucose transporter protein type 1 in breast cancer[J]. Cancer Lett. 2015;356(2 Pt B):410-417.
[16] Goos JA, de Cuba EM, Coupé VM, et al. Glucose Transporter 1 (SLC2A1) and Vascular Endothelial Growth Factor A (VEGFA) Predict Survival After Resection of Colorectal Cancer Liver Metastasis[J]. Ann Surg. 2016;263(1):138-145.
[17] Li C, Chen Q, Zhou Y, et al. S100A2 promotes glycolysis and proliferation via GLUT1 regulation in colorectal cancer[J]. FASEB J. 2020;34(10):13333-13344.
[18] Liu YX, Feng JY, Sun MM, et al. Aspirin inhibits the proliferation of hepatoma cells through controlling GLUT1-mediated glucose metabolism[J]. Acta Pharmacol Sin. 2019;40(1):122-132.
[19] Lin Q, Jiang H, Lin D. Circular RNA ITCH downregulates GLUT1 and suppresses glucose uptake in melanoma to inhibit cancer cell proliferation[J]. J Dermatolog Treat. 2021;32(2):231-235.
[20] Al Hasawi N, Alkandari MF, Luqmani YA. Phosphofructokinase: a mediator of glycolytic flux in cancer progression[J]. Crit Rev Oncol Hematol. 2014;92(3):312-321.
[21] Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis[J]. Nat Rev Mol Cell Biol. 2018;19(2):121-135.
[22] Oppermann H, Faust H, Yamanishi U, Meixensberger J, Gaunitz F. Carnosine inhibits glioblastoma growth independent from PI3K/Akt/mTOR signaling[J]. PLoS One. 2019; 14(6):e0218972.
[23] Flögel U, Willker W, Leibfritz D. Determination of de novo synthesized amino acids in cellular proteins revisited by 13C NMR spectroscopy[J]. NMR Biomed. 1997; 10(2):50-58.